Almirall and Forest complete Phase III COPD studies
This article was originally published in Scrip
The Spanish company Almiralland US-based Forest Laboratories have announced the completion of two pivotal Phase III studies designed to assess the efficacy and safety of aclidinium bromide – an anticholinergic bronchodilator – in moderate to severe chronic obstructive pulmonary disease (COPD) patients. Preliminary top-line results are expected later this year. Both trials, one conducted in Europe and the other in North America, were double-blind, multi-centred, parallel-group and placebo-controlled. Patients were aged at least 40, and had a 10 pack year smoking history. The primary end point of both trials is pre-dose forced expiratory volume in one second (a common measure of pulmonary function) versus placebo. Almirall and Forest are co-developing aclidinium bromide; the latter is to market the product in the US while Almirall retains the rights for the rest of the world.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.